Congenital Disorder of Glycosylation Type 1i (CDG-1i)

Congenital Disorder of Glycosylation type 1i (CDG-1i) is a very rare, inherited metabolic disease. It happens because a small change (mutation) in a gene called ALG2 stops a cell enzyme from working the way it should. This enzyme normally adds mannose sugars to a growing sugar chain inside the cell’s endoplasmic reticulum. That sugar chain is then attached to many proteins in a process called N-linked glycosylation. When ALG2 does not work well, many body proteins do not get the right sugar coating. We call this hypoglycosylation. Without proper sugar coating, proteins cannot fold, travel, and function normally. This affects many organs at the same time, especially the brain, nerves, muscles, liver, heart, and the blood clotting system. Symptoms often start in infancy or early childhood. There is no single cure yet. Treatment focuses on supportive care, symptom control, and preventing complications.

What is happening in the body

All cells build complex “sugar trees” called oligosaccharides. Cells assemble these on a lipid carrier (dolichol-PP) in the endoplasmic reticulum. Later, they transfer the full sugar tree to a protein, making a glycoprotein. The ALG2 enzyme adds mannose sugars in two directions (alpha-1,3 and alpha-1,6 branches) very early in this assembly line. If ALG2 is weak or missing, the sugar tree stays incomplete. Many proteins leave the factory with the wrong sugar coat. This causes misfolded proteins, slower protein traffic, and faster protein breakdown. Because glycoproteins are everywhere—in brain synapses, muscle fibers, heart muscle, liver cells, hormone receptors, and clotting factors—the disease is multi-system.

Congenital disorder of glycosylation type 1i is a very rare, inherited metabolic disease. In this condition, the body has trouble building the sugar chain (called an N-glycan) that must be attached to many proteins so they work properly. The exact problem is a fault in a gene called ALG2. This gene makes an enzyme that adds mannose sugars early in the building process inside the endoplasmic reticulum (ER) of the cell. When ALG2 does not work well because of gene changes (variants), many proteins are made with incomplete sugar chains. As a result, many organs can be affected, especially the brain, nerves, eyes, muscles, and blood clotting system. The disorder is autosomal recessive, meaning a child becomes affected when they receive one faulty ALG2 gene from each parent. PMC+1

Scientists group CDG into Type I and Type II based on where the problem occurs. Type I, like CDG-Ii, affects the early assembly or transfer of the whole sugar chain to the protein; Type II affects later trimming and processing steps. A common first clue for any N-linked CDG is an abnormal transferrin glycoform pattern in blood tests. PubMed+1

Other names

• ALG2-CDG (preferred modern name)

• Congenital disorder of N-linked glycosylation, type Ii

• Alpha-1,3-mannosyltransferase 2 congenital disorder of glycosylation

• CDG-Ii (older shorthand used in research papers)
  All of these names refer to the same condition caused by biallelic variants in ALG2. CDG Hub+1

Types

ALG2 attaches the second and third mannose sugars to the growing lipid-linked oligosaccharide (the “starter” sugar chain) in the ER. Faulty ALG2 means these mannose steps are skipped or inefficient, so the chain is incomplete when it is transferred to proteins. Those proteins then misfold or do not reach the right places, which can disturb brain development, eye formation, muscle function, and blood clotting. PMC+1

Doctors now recognize a spectrum rather than rigid subtypes:

1. Severe, multisystem form (classic CDG-Ii): early-infant onset with developmental delay, low muscle tone, seizures (including infantile spasms), eye defects (iris coloboma, cataracts), and abnormal clotting factors. Genetic Diseases Info Center

2. Milder neuromuscular-junction form (ALG2-congenital myasthenic syndrome, ALG2-CMS): mainly fatigable weakness, droopy eyelids, and exercise intolerance, with less multi-organ involvement. Both presentations come from ALG2 variants. CDG Hub

(Different families can have different severities even with changes in the same gene.) CDG Hub

---

Causes

Important note: The primary cause of CDG-Ii is having two non-working copies of the ALG2 gene. The points below explain the many ways this can happen or what can influence how it looks in a person or family.

1. Biallelic ALG2 variants (autosomal recessive): a child inherits one faulty copy from each parent. This is the root cause. Genetic Diseases Info Center

2. Missense variants in ALG2: a single amino-acid change can reduce enzyme activity. PMC

3. Nonsense variants: create a stop signal early; the enzyme is truncated and inactive. PMC

4. Frameshift variants: small insertions/deletions shift the code and cripple ALG2. PMC

5. Splice-site variants: disrupt cutting/joining of RNA, lowering normal enzyme levels. PMC

6. Large deletions/duplications in ALG2: remove or duplicate chunks of the gene. PMC

7. Compound heterozygosity: two different ALG2 variants (one from each parent) combine to cause disease. PMC

8. Founder variants within a population: the same ALG2 change appears in unrelated families from a shared ancestor. PMC

9. Consanguinity (parents related by blood): raises the chance a child gets two copies of the same rare ALG2 variant. Genetic Diseases Info Center

10. Reduced residual ALG2 activity: some variants weaken but do not remove function; this often leads to milder disease. CDG Hub

11. Very low ALG2 activity: little to no enzyme function typically causes severe multisystem disease. CDG Hub

12. Modifier genes in glycosylation pathways: changes in other glycosylation genes may worsen or soften the picture (concept shown across CDG as a group). BioMed Central

13. Cellular stress in the ER: mis-glycosylated proteins trigger stress responses that add to symptoms. (General CDG mechanism.) BioMed Central

14. Developmental sensitivity of the brain and eyes: these organs rely heavily on correctly glycosylated proteins, so ALG2 defects hit them hard. (General CDG principle.) BioMed Central

15. Abnormal transferrin glycoforms reflecting systemic impact: this is a biomarker of the underlying cause, not the cause itself, but it mirrors the defect’s reach. NCBI

16. Random (de novo) variants in ALG2: rarely, a new variant arises in a child; if the second copy is also non-working, disease occurs. BioMed Central

17. Gene conversion or complex rearrangements: unusual DNA events can damage ALG2 sequence. PMC

18. Promoter/regulatory variants: changes that lower ALG2 gene expression. PMC

19. Nonsense-mediated decay of ALG2 RNA: some variants trigger RNA destruction, reducing enzyme amounts. PMC

20. Environmental and nutritional stressors don’t cause CDG-Ii, but illness or poor nutrition can unmask or worsen symptoms in someone who already has ALG2-CDG. (General CDG observation.) BioMed Central

---

Common symptoms and signs

1. Developmental delay: slower milestones for sitting, crawling, walking, and speech because the brain does not develop normally when proteins are poorly glycosylated. Genetic Diseases Info Center

2. Low muscle tone (hypotonia): floppy muscles in babies; later, poor head control and weak core strength. Genetic Diseases Info Center

3. Seizures / infantile spasms: bursts of abnormal brain activity; sometimes hard to control. Genetic Diseases Info Center

4. Eye defects (iris coloboma, cataracts): parts of the eye do not form completely or become cloudy, reducing vision. Orpha.net

5. Feeding difficulty and failure to thrive: weak suck/swallow, reflux, or vomiting make weight gain hard. (Common across CDG.) rarediseases.org

6. Abnormal blood clotting tests: low or imbalanced clotting factors can lead to easy bruising or bleeding. Genetic Diseases Info Center

7. Facial differences (dysmorphism): features like high forehead, unusual hairline, or eye position; not harmful themselves but a diagnostic clue (noted in related N-linked CDG). Orpha.net

8. Microcephaly: smaller head size from reduced brain growth. CDG Hub

9. Fatigable weakness / droopy eyelids (ptosis): in the milder ALG2-CMS form, muscles tire quickly, especially around the eyes and limbs. CDG Hub

10. Learning difficulties / intellectual disability: ranges from mild to severe depending on how much enzyme function remains. CDG Hub

11. Abnormal muscle reflexes or coordination: poor balance and clumsy movement because of brain and muscle involvement. (General CDG feature.) NCBI

12. Hearing problems: some individuals have sensorineural hearing loss. (Reported across N-linked CDG.) NCBI

13. Liver involvement: elevated liver enzymes or enlarged liver in some cases. (Across CDG family.) rarediseases.org

14. Heart or kidney findings (less common): structural or function issues have been described across CDG; clinicians screen if symptoms suggest them. rarediseases.org

15. Recurrent infections: can occur in CDG due to multiple system effects; evaluation is individualized. rarediseases.org

---

Diagnostic tests

Big picture: Doctors mix clinical clues with screening of transferrin glycoforms and genetic testing of ALG2. Extra tests check which organs are involved and guide care. NCBI

A) Physical examination (bedside checks)

1. Growth and nutrition review: weight, length/height, and head size to detect failure to thrive or microcephaly. rarediseases.org

2. Neurologic exam: tone, reflexes, coordination, and signs of seizures to gauge brain and muscle involvement. NCBI

3. Eye examination (external): look for cataracts/coloboma clues before detailed eye testing. Orpha.net

4. Craniofacial assessment: subtle facial features that point toward an N-linked CDG. NCBI

5. Abdominal exam: liver and spleen size by palpation to screen for organ enlargement. rarediseases.org

B) “Manual” functional tests (simple clinic-room checks)

6. Fatigability testing: repeated arm lifts or sustained up-gaze to look for droopy eyelids and muscle weakness typical of ALG2-CMS. CDG Hub

7. Feeding and swallow assessment: bedside check of suck/swallow; may lead to formal swallow study if poor growth. rarediseases.org

8. Developmental screening tools: age-appropriate checklists to map delays and set therapy goals. NCBI

9. Balance and gait observation: simple walking/standing tests to document coordination problems. NCBI

10. Vision function check: tracking and fixation tests to triage for ophthalmology. Orpha.net

C) Laboratory and pathological tests

11. Transferrin glycoform analysis (isoelectric focusing or mass spectrometry): the key screening test for N-linked CDG; CDG-Ii gives a Type I pattern. NCBI+1

12. Plasma N-glycan profiling: complementary biochemical testing to support a CDG diagnosis. Children’s Hospital of Philadelphia

13. Gene testing for ALG2 (sequencing + deletion/duplication): confirms CDG-Ii by finding biallelic pathogenic variants. Frontiers

14. Clotting studies: PT/INR, aPTT, and specific coagulation factors (e.g., antithrombin, protein C/S) since clotting proteins can be under-glycosylated. Genetic Diseases Info Center

15. Liver tests: ALT, AST, GGT, albumin, and bilirubin to look for liver involvement seen across CDG. rarediseases.org

16. Metabolic panel and CK: general status and muscle enzyme baseline to guide care. (General CDG work-up.) NCBI

D) Electrodiagnostic tests

17. EEG: evaluates seizures/infantile spasms and helps guide anti-seizure treatment. Genetic Diseases Info Center

18. Nerve conduction studies and EMG with repetitive nerve stimulation: looks for neuromuscular-junction transmission defects typical of the ALG2-CMS presentation. CDG Hub

19. Evoked potentials (visual/auditory): checks pathways related to vision and hearing if impairment is suspected. (Used across CDG.) NCBI

E) Imaging tests

20. Brain MRI: may show structural differences or delayed myelination; supports the neurological picture and rules out other causes. (Common across CDG evaluations.) NCBI

Non-pharmacological treatments

1. Individualized nutrition therapy: A dietitian plans high-calorie, high-protein feeds and safe textures. Purpose: support growth and healing. Mechanism: increases caloric intake and reduces aspiration risk.

2. Feeding therapy (SLP/OT): Trains safe swallow, pacing, and positioning. Purpose: reduce choking and improve intake. Mechanism: strengthens oral–motor patterns and airway protection.

3. Thickened liquids or texture modification: Adjusts consistency to prevent aspiration. Purpose: safer swallowing. Mechanism: slows flow and improves bolus control.

4. Gastrostomy tube (care and training): If oral intake is unsafe or insufficient. Purpose: reliable nutrition and medications. Mechanism: bypasses unsafe swallow.

5. Physiotherapy (PT): Builds core strength, endurance, and balance. Purpose: improve mobility and prevent contractures. Mechanism: neuromuscular re-education and muscle conditioning.

6. Occupational therapy (OT): Works on fine motor skills and daily living tasks. Purpose: independence in self-care and play. Mechanism: task-specific, repetitive training.

7. Speech-language therapy (communication): Supports speech or AAC devices. Purpose: better communication and learning. Mechanism: structured language and augmentative systems.

8. Early intervention and special education: Tailored learning plan from infancy onward. Purpose: maximize developmental potential. Mechanism: enriched environment and practice.

9. Respiratory physiotherapy: Chest physiotherapy and airway clearance. Purpose: prevent pneumonia. Mechanism: mobilizes secretions and improves ventilation.

10. Orthotic supports (AFOs, seating): Stabilize joints and posture. Purpose: safer standing and walking. Mechanism: external alignment and energy efficiency.

11. Vision therapy and low-vision aids: Optimize functional vision. Purpose: better reading, play, and safety. Mechanism: compensatory strategies and magnification.

12. Hearing services (hearing aids/therapy): Treats hearing loss. Purpose: improved speech and learning. Mechanism: amplification and auditory training.

13. Seizure first-aid training for caregivers: Clear steps during a seizure. Purpose: safety and rapid response. Mechanism: reduces injury and delays.

14. Infection-prevention practices: Hand hygiene, vaccines, prompt care for fevers. Purpose: fewer severe infections. Mechanism: lowers exposure and boosts immunity.

15. Sleep hygiene and positioning: Regular bedtime routine; safe sleep positions. Purpose: better rest and breathing. Mechanism: stabilizes circadian rhythm and airway.

16. Pain and spasm management without drugs (heat, stretching): Gentle methods for aches and tightness. Purpose: comfort and range of motion. Mechanism: reduces muscle guarding.

17. Psychological support and counseling: For family stress and coping. Purpose: resilience and adherence. Mechanism: cognitive-behavior tools and support groups.

18. Social work and care coordination: Links services, equipment, and benefits. Purpose: reduce caregiver burden. Mechanism: navigation and advocacy.

19. Advance care planning (when severe): Aligns care with family goals. Purpose: informed choices and comfort. Mechanism: shared decision-making.

20. Genetic counseling: Explains inheritance and options for future pregnancies. Purpose: informed family planning. Mechanism: risk assessment and testing discussion.

---

Drug treatments

Important safety note: Doses below are typical references; actual dosing must be individualized by a clinician, especially for infants and children.

1. Levetiracetam (antiseizure): 10–60 mg/kg/day divided bid. Timing: daily. Purpose: control seizures. Mechanism: SV2A modulation. Side effects: irritability, somnolence.

2. Valproate (antiseizure): 10–60 mg/kg/day; monitor levels. Purpose: seizure control. Mechanism: GABA increase. Side effects: liver toxicity, thrombocytopenia—use cautiously with liver or coagulation issues.

3. Clobazam (benzodiazepine antiseizure): 0.25–1 mg/kg/day. Purpose: adjunct for refractory seizures. Mechanism: GABA-A enhancement. Side effects: sedation, tolerance.

4. Topiramate (antiseizure): 1–9 mg/kg/day. Purpose: seizures/migraine. Mechanism: Na+ channels, GABA, glutamate. Side effects: appetite loss, acidosis, stones.

5. Phenobarbital (antiseizure neonates): 3–5 mg/kg/day. Purpose: neonatal seizures. Mechanism: GABAergic. Side effects: sedation, cognitive slowing.

6. Carnosine/levocarnitine? (Skip—see supplements later.)

7. Omeprazole (PPI for reflux): 1 mg/kg/day. Purpose: reduce reflux and aspiration risk. Mechanism: blocks acid pumps. Side effects: diarrhea, low magnesium with long use.

8. Erythromycin (prokinetic low dose): 1–3 mg/kg/dose q8h. Purpose: improve gastric emptying. Mechanism: motilin receptor agonist. Side effects: cramps, QT risk.

9. Ondansetron (antiemetic): 0.15 mg/kg/dose up to 8 mg, tid prn. Purpose: vomiting control. Mechanism: 5-HT3 blockade. Side effects: constipation, QT prolongation.

10. Vitamin K (coagulation support): per clinician protocol. Purpose: correct prolonged INR if vitamin-K responsive. Mechanism: cofactor for clotting proteins. Side effects: rare anaphylactoid with IV push.

11. Antifibrinolytics (tranexamic acid): 10 mg/kg q8h in bleeds per protocol. Purpose: reduce mucosal bleeding. Mechanism: blocks plasminogen activation. Side effects: thrombosis risk (assess per case).

12. Antithrombin concentrate: individualized if antithrombin is very low with thrombosis risk. Purpose: balance coagulation. Mechanism: replaces missing inhibitor. Side effects: infusion reactions.

13. Beta-blocker (propranolol) for cardiomyopathy/arrhythmia as indicated: dosing per cardiology. Purpose: rate control, reduce workload. Mechanism: beta-adrenergic blockade. Side effects: bradycardia, hypoglycemia risk in infants.

14. ACE inhibitor (enalapril) for cardiomyopathy as indicated: 0.1–0.5 mg/kg/day. Purpose: afterload reduction. Mechanism: RAAS blockade. Side effects: hypotension, renal changes, cough.

15. Diuretics (furosemide) if heart failure/edema: 0.5–1 mg/kg/dose. Purpose: remove excess fluid. Mechanism: loop diuretic. Side effects: electrolytes loss, dehydration.

16. Antibiotics per culture for infections: dosing by organism. Purpose: treat pneumonia/UTIs. Mechanism: pathogen-specific. Side effects: vary; watch for C. difficile with broad-spectrum agents.

17. Bronchodilator (albuterol) for reactive airways: 2.5 mg neb prn. Purpose: ease wheeze. Mechanism: beta-2 agonist. Side effects: tremor, tachycardia.

18. Melatonin (sleep): 1–5 mg 30–60 min before bedtime. Purpose: improve sleep. Mechanism: circadian support. Side effects: morning drowsiness.

19. Baclofen (spasticity if present): 0.5–2 mg/kg/day divided. Purpose: reduce tone/spasms. Mechanism: GABA-B agonist. Side effects: weakness, sedation.

20. Polyethylene glycol (constipation): 0.4–1 g/kg/day. Purpose: soft stool. Mechanism: osmotic water retention. Side effects: bloating, cramps.

21. Medium-chain triglyceride (MCT) oil as a medical food adjunct (if malabsorption): dose per dietitian. Purpose: easier calories. Mechanism: rapid absorption without bile dependence. Side effects: diarrhea if excessive.

Note: Mannose therapy helps a different CDG subtype (MPI-CDG, formerly CDG-Ib). Current evidence does not support mannose therapy in ALG2-CDG (CDG-1i).

---

Dietary molecular supplements

Always discuss supplements with your clinician, especially for infants and children.

1. Multivitamin with minerals: age-appropriate daily. Function: fills micronutrient gaps. Mechanism: supports enzymes and tissue repair.

2. Vitamin D3: typical 400–1000 IU/day (or per level). Function: bone and immune support. Mechanism: regulates calcium and immunity.

3. Vitamin K (nutritional): diet-based or drops if low (per labs). Function: supports clotting factor activation. Mechanism: gamma-carboxylation cofactor.

4. Omega-3 fatty acids (fish oil): 30–50 mg/kg/day EPA+DHA. Function: anti-inflammatory; may support heart and brain. Mechanism: membrane and eicosanoid effects.

5. L-Carnitine: 50–100 mg/kg/day if low. Function: fatty acid transport for energy. Mechanism: shuttles long-chain fats into mitochondria.

6. Coenzyme Q10: 2–5 mg/kg/day. Function: mitochondrial electron transport support. Mechanism: aids ATP generation.

7. MCT oil: dietitian-guided teaspoons/day. Function: dense calories; easier absorption. Mechanism: portal absorption independent of bile salts.

8. Probiotics (clinician-approved strain): per label. Function: gut health and fewer infections. Mechanism: microbiome balancing.

9. Magnesium (if low or cramps): dose per age and labs. Function: muscle and nerve function. Mechanism: cofactor for ATP reactions.

10. Zinc (if deficient): per labs/age. Function: growth, immune, wound healing. Mechanism: enzyme cofactor and gene regulation.

---

Medicines or approaches often called “immunity booster / regenerative / stem-cell”

1. Vaccinations (standard schedule, plus clinician-guided additions): Dosage: per national program. Function: prevent severe infections. Mechanism: trains adaptive immunity.

2. Immune globulin (IVIG) if documented antibody deficiency: Dose per kg monthly. Function: infection prevention. Mechanism: provides pooled protective antibodies.

3. Nutritional rehabilitation as “immune support”: Calorie/protein targets by dietitian. Function: restores immune cell function. Mechanism: corrects protein–energy malnutrition.

4. Physiologic vitamin D optimization (not mega-doses): Dose per level. Function: modulates immunity. Mechanism: vitamin D receptors on immune cells.

5. Experimental gene therapy / gene editing (research-only): No approved dosing. Function: future disease-modifying hope. Mechanism: restore ALG2 activity. Note: investigational, not standard care.

6. Hematopoietic stem-cell transplant (HSCT): Not established for ALG2-CDG. In theory, HSCT replaces marrow immune cells but does not correct glycosylation across the body. Only considered within a research context if ever proposed; risks are high.

Bottom line: solid, proven “immune boosters” are vaccines, nutrition, and treating deficiencies. Be cautious with unproven products.

---

Surgeries or procedures

1. Gastrostomy tube placement (G-tube): A feeding tube into the stomach. Why: when swallowing is unsafe or oral intake is not enough.

2. Fundoplication (select cases): Tightens the valve at the top of the stomach. Why: severe reflux causing aspiration and poor growth despite medical therapy.

3. Orthopedic procedures (e.g., tendon releases, scoliosis support): Why: improve positioning, reduce pain, and aid caregiving in children with significant tone problems.

4. Strabismus surgery: Re-aligns eye muscles. Why: persistent eye misalignment that affects vision or causes symptoms.

5. Cardiac procedures (device/defibrillator) if indicated: Why: treat dangerous rhythm problems or advanced cardiomyopathy in selected patients after cardiology evaluation.

---

Prevention strategies

1. Genetic counseling for families with an affected child.

2. Carrier testing of parents and at-risk relatives.

3. Prenatal or preimplantation genetic testing in future pregnancies if the familial ALG2 variants are known.

4. Routine vaccinations on time for the child and close contacts.

5. Strict hand hygiene and infection-control habits at home and school.

6. Early feeding assessment to prevent aspiration and malnutrition.

7. Regular therapy services (PT/OT/SLP) to prevent contractures and deconditioning.

8. Fall prevention and safe mobility plans to avoid injuries.

9. Dental care and oral hygiene to reduce aspiration risk and infections.

10. Emergency care plan (seizure action plan, fever plan) shared with caregivers and school.

---

When to see a doctor (red flags)

See a doctor urgently for: new or worsening seizures; breathing trouble; blue lips; severe vomiting; signs of dehydration; very poor feeding; unusual sleepiness; fainting spells; sudden swelling; fast weight gain; bleeding that does not stop; black stools; or a fever in a very young infant. Schedule routine visits for growth checks, therapy reviews, vaccination updates, new feeding problems, behavior changes, or school concerns.

---

What to eat” and “what to avoid

What to eat:

1. Balanced meals with adequate calories and protein to support growth.

2. Soft or pureed textures if advised by the feeding team.

3. Thickened liquids if swallow studies say they are safer.

4. Frequent small meals to reduce fatigue and reflux.

5. Healthy fats (olive oil, avocado, MCT oil per dietitian) for dense energy.

What to avoid:

1. Thin liquids if they cause coughing or aspiration.
2. Hard, dry, or crumbly foods that are hard to chew.
3. Very acidic or spicy foods if reflux is severe.
4. Excess added sugar that displaces needed protein and micronutrients.
5. Unregulated supplements promising “cures” without medical oversight.

---

FAQs

1) Is CDG-1i the same as ALG2-CDG?
Yes. CDG-1i is another name for ALG2-CDG, caused by mutations in the ALG2 gene.

2) How is it inherited?
Autosomal recessive. A child must receive one non-working ALG2 gene from each parent.

3) When do symptoms start?
Often in infancy or early childhood, but severity and timing vary.

4) What is the first test doctors do?
Many centers start with transferrin glycoform analysis and confirm with genetic testing.

5) Does mannose therapy help?
No, mannose helps a different subtype (MPI-CDG). It is not effective for ALG2-CDG.

6) Can diet cure this disease?
Diet cannot cure the genetic defect, but smart nutrition supports growth, energy, and immunity.

7) Are seizures common?
Seizures occur in some children. Modern antiseizure medicines can help control them.

8) Will my child walk or talk?
Outcomes vary. Early therapies improve skills and independence but cannot guarantee milestones.

9) Is the liver always involved?
Not always. Some children have normal liver tests; others have low albumin or clotting issues.

10) Can the heart be affected?
Yes in a subset. Cardiology checks (ECG, echocardiogram) are recommended if symptoms or exam suggest involvement.

11) Is there a cure now?
There is no approved cure yet. Research into gene-directed therapies is ongoing.

12) Is stem-cell transplant a treatment?
No standard role for ALG2-CDG. HSCT does not fix glycosylation in all tissues.

13) What about life expectancy?
It depends on severity, complications, and access to supportive care. Some children have severe, early-life disease; others live longer with support.

14) Can another child in the family be tested?
Yes. When the family’s ALG2 variants are known, siblings and future pregnancies can be tested.

15) What helps most day-to-day?
Early therapies (PT/OT/SLP), safe feeding, seizure control, infection prevention, and coordinated care.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 12, 2025.